AI Insight
Researchers developed Dr.BUG, an AI-based clinical decision support system designed to assist in the management of carbapenem-resistant Gram-negative bacterial (CRGNB) infections. The system integrates multi-task predictive modeling across four clinical outcomes, including treatment efficacy, patient survival, polymyxin resistance, and treatment duration, using routinely available clinical variables. Validated across development, temporal, and external cohorts derived from the MIMIC-IV dataset, the models demonstrated that reduced feature sets matched or outperformed full-feature models in 82% of optimized-metric comparisons, and the system generated individualized antibiotic regimen rankings that clinicians retrospectively associated with higher predicted survival probabilities in non-survivor cases.
Why it matters
CRGNB infections represent a growing global health threat with very limited treatment options, and a validated decision support tool capable of personalizing antibiotic recommendations could meaningfully improve clinical outcomes and guide stewardship efforts in high-complexity infectious disease settings.
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Carbapenem-resistant Gram-negative bacteria (CRGNB) infections remain difficult to manage because treatment decisions must balance heterogeneous patient risk, limited antibiotic options, potential toxicity and emerging resistance. Clinical care in this setting requires not only single-endpoint risk prediction, but also decision-support frameworks that can jointly enable prognosis assessment, result interpretation, and individualized treatment comparison. Here we present Dr.BUG, an interactive clinical AI agent for personalized decision support in CRGNB infection. Dr.BUG integrates stable feature-set selection, multi-task prognostic modelling, interpretability analysis and model-based simulation of antibiotic regimen recommendation into a unified workflow. Using a development cohort, a temporally independent validation cohort, and external cohorts from the MIMIC-IV dataset, we developed and validated models for four clinically relevant tasks: clinical efficacy, survival outcome, polymyxin resistance and treatment duration. Model inputs were derived primarily from routinely available and relatively low-cost clinical variables, supporting translational feasibility. Across the major tasks, selected-feature models matched or exceeded the performance of their full-feature counterparts while using fewer variables, as reflected in 82.0% of optimized-metric comparisons in the development cohort, and remained robust in both temporal and external validation. Dr.BUG further provided both population-level and patient-level interpretability and generated individualized rankings of candidate antibiotic regimens. In the retrospective analysis of non-survivors, clinician review suggested that regimens recommended by Dr.BUG might be associated with higher predicted survival probabilities. These findings support a broader role for clinical AI in complex drug-resistant infections, extending its utility from offline risk prediction to interpretable, deployable, and personalized decision support.